Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019693 (
HIV
)
170,526
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The relation of the initial products of the
HIV
-1 gag gene to the final products was determined in virus samples and cell fractions of infected H9 and Jurkat-tat cell cultures. The proteins were identified by immunoblotting with pooled sera from AIDS patients or monoclonal antibodies. The proportion in the virions of gag precursor proteins and the products of their proteolytic cleavage varied according to the maturity of the virus particles as determined by electron microscopy. The distribution of viral gag proteins in the cell fractions was determined 2, 4, and 24 h after infection. Treatment of cells with cycloheximide to block de novo protein synthesis did not significantly affect the results. Gag proteins containing the N terminus of the precursor
p55
(including
p55
, the intermediate precursors p41(45) and p39, and mature protein p17) were found in the cell nuclei up to 24 h after infection. The major core protein p24 was located in the cytoplasmic fraction. These data strongly suggest that gag precursors from the
p55
N terminus and the matrix protein p17 enter the infected cell separately from the major core protein p24, or become separated from it in the cytoplasm.
...
PMID:HIV-1 gag proteins in virions and in infected cell fractions. 175 61
Sera from 124 persons in high risk groups were analyzed including homosexuals, blood recipients, and spouses or siblings from AIDS patients. In this study, 118 individuals had a positive ELISA for anti-
HIV
antibodies. Six persons had a complete immunodeficiency syndrome and a negative ELISA test. In the Western blot, 111 sera were positive, four negative, and nine scored indeterminate; four of the latter converted to positive when retested three months later. Antibodies present in the positive sera were directed against the
HIV
gp 41 kD in 100% of the cases and against the gp 120 kD in 82%. Frequency of recognition of
p55
kD was 96% but p18 kD was only 42%.
...
PMID:[Immunoelectroblotting in Mexican subjects at high risk for infection with human immunodeficiency virus (HIV)]. 181 69
The peptide derivative Ro 31-8959 is a potent and selective inhibitor of the aspartic proteinases encoded by
HIV
-1 and
HIV
-2 and it arrests the growth of both viruses in cell culture. We have demonstrated similar effects against the simian immunodeficiency virus SIVmac251 in the human T-cell line, C8166 (ED50 = 6nM) with a therapeutic index of 4,500. The antiviral activity of Ro 31-8959 was 250 and 22 times greater than that of ddI and ddC, respectively. The mode of action was confirmed by accumulation of the polyprotein
p55
with concomitant reduction of the cleavage product, p27, and by the production of immature virions.
...
PMID:The inhibitory activity of a peptide derivative against the growth of simian immunodeficiency virus in C8166 cells. 185 Feb 56
The vaccinia virus expression system was used to determine the role of human immunodeficiency virus type 1 (HIV-1) protease in viral morphogenesis and maturation. The unprocessed
p55
gag precursor polyprotein alone was assembled to form
HIV
-1 particles which budded from cells. The particles were spherical and immature, containing an electron-dense shell in the particle submembrane; there was no evidence of core formation. Expression of both gag and pol proteins from a recombinant containing the complete gag-pol coding sequences resulted in intracellular processing of gag-pol proteins and the production of mature particles with electron-dense cores characteristic of wild-type
HIV
virions. To ascertain the role of protein processing in particle maturation, the pol ORF in the gag-pol recombinant was truncated to limit expression of the pol gene to the protease domain. With this recombinant expressing
p55
gag and protease, intracellular processing was observed. Some of the resultant particles were partially mature and contained processed gag protein subunits. In contrast, particle maturation was not observed when the HIV-1 protease and
p55
gag were coexpressed from separate recombinants, despite evidence of intracellular gag processing. These findings suggest that HIV-1 protease must be an integral component of the full-length gag-pol precursor for optimal processing and virion maturation.
...
PMID:Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing by gag-pol protease. 187 82
Recombinant adenovirus vectors expressing the entire gag (
p55
) or CA (p24) region of human immunodeficiency virus type 1 (HIV-1) were constructed by inserting the appropriate
HIV
DNA sequences into the E3 region of human adenovirus type 5 (Ad5) with and without an exogenous SV40 early promoter. The infectious recombinant adenoviruses Adgag1, AdSVgag1, and AdSVCA1 were shown to express the appropriate HIV-1 antigens in human cells in vitro, as measured by immunoprecipitation and p24 antigen capture assays. Using the p24 antigen capture assay,
HIV
antigen expressed by AdSVCA1 was detected earlier in infection and in greater amounts than that produced by either Adgag1 or AdSVgag1. In studies concerning the immunogenicity of these vectors, Balb/c (H-2d) mice given a single intraperitoneal injection of 10(7) or 10(8) plaque-forming units of purified vector developed serum antibodies to p24, detected by Western blotting, by 2 weeks postinjection. In the preliminary test of the immunogenicity of the recombinant adenovirus vectors in primates, two of four rhesus macaque monkeys generated antibodies to HIV-1 p24 following two injections of AdSVCA1. As expected, monkeys injected with control adenovirus failed to show any anti-HIV response, and none of the monkeys showed any adverse reactions following infection with either recombinant or control adenoviruses. These results suggest that adenovirus vectors have considerable potential in the study of possible immune therapies for
HIV infection
.
...
PMID:Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. 190 14
The immunoreactivity of serum samples from
HIV
-2 infected persons was studied by radioimmunoprecipitation assay (RIPA) in homo- and heterotypic variants. In homotypic RIPA all sera studied have precipitated the viral glycoprotein with the high molecular weight, gp170. Some samples were active for gag-gene products, p57 and p26 in homotypic RIPA. Most these samples were also active for heterotypic gag-protein of
HIV
-1 serotype,
p55
and p24. On the other hand anti-gag reactivity of one sample was limited only by homotypic activity. Some causes of this phenomena as well as its significance for serodiagnosis of
HIV infection
are discussed.
...
PMID:[Group- and type-specific antibodies to the gag-gene protein p26 of the human immunodeficiency virus immunological type 2 in infected patients]. 205 5
A new method is described for determining molecular structures from NMR data. The approach utilizes 2D NOESY back-calculations to generate simulated spectra for structures obtained from distance geometry (DG) computations. Comparison of experimental and back-calculated spectra, including analysis of cross-peak buildup and auto-peak decay with increasing mixing time, provides a quantitative measure of the consistence between the experimental data and generated structures and allows for use of tighter interproton distance constraints. For the first time, the "goodness" of the generated structures is evaluated on the basis of their consistence with the actual experimental data rather than on the basis of consistence with other generated structures. This method is applied to the structure determination of an 18-residue peptide with an amino acid sequence comprising the first zinc fingerlike domain from the gag protein
p55
of
HIV
. This is the first structure determination to atomic resolution for a retroviral zinc fingerlike complex. The peptide [Zn(p55F1)] exhibits a novel folding pattern that includes type I and type II NH-S tight turns and is stabilized both by coordination of the three Cys and one His residues to zinc and by extensive internal hydrogen bonding. The backbone folding is significantly different from that of a "classical" DNA-binding zinc finger. Residues C(1)-F(2)-N(3)-C(4)-G(5)-K(6) fold in a manner virtually identical with the folding observed by X-ray crystallography for related residues in the iron domain of rubredoxin; superposition of all main-chain and Cys side-chain atoms of residues C(1)-K(6) of Zn(p55F1) onto residues C(6)-Y(11) and C(39)-V(44) of rubredoxin gives RMSDs of 0.46 and 0.35 A, respectively. The side chains of conservatively substituted Phe and Ile residues implicated in genomic RNA recognition form a hydrophobic patch on the peptide surface.
...
PMID:High-resolution structure of an HIV zinc fingerlike domain via a new NMR-based distance geometry approach. 210 40
We produced three murine monoclonal antibodies (mAbs) against the
HIV
-1 proteins. These three mAbs, namely CA-1, CA-2, CA-4, were IgG1 and all reacted with p24 on the
HIV
-1 Western blot. One of the mAbs, CA-4, also recognized p13, p21, p28, p29, p32, p39, p47,
p55
on the Biotech/Du Pont
HIV
-1 Western blot strips and p21, p24, p28, p29, p39, p47,
p55
, p68, p80, p96; p110 on the Bio-Rad strips. CA-4 did not react with H-9 cell lysate nor with other retroviral antigens such as HTLV-1 or
HIV
-2 proteins. The binding of CA-4 to
HIV
-1 proteins was not blocked by deglycosylation. All three mAbs reacted with recombinant DNA derived capsid protein (p24) of
HIV
-1. These results suggest that many proteins in the
HIV
-1 Western blot contain antigenic epitope(s) similar to that of p24.
...
PMID:An anti-p24 monoclonal antibody shows cross-reactivity with multiple HIV-1 proteins. 211 62
Yeast-expressed
p55
precursor core protein of human immunodeficiency virus type 1 (HIV-1) was used to immunize chimpanzees. The animals developed high titers of antibodies to
p55
as well as to the p24 and p17 mature cleavage products of the core precursor. Virus-neutralizing antibodies were not elicited. The induced immune responses did not prevent establishment of
HIV
-1 infection following challenge of one immunized chimpanzee with live virus.
...
PMID:Yeast-expressed p55 precursor core protein of human immunodeficiency virus type 1 does not elicit protective immunity in chimpanzees. 212 81
We analyzed nine sera from persons unlikely to be
HIV
infected which had an IgG reactivity directed against
HIV
-1 p24, and in two cases also to its precursor
p55
, but to no other
HIV
proteins, nor to proteins of the H9 host cell, in electrophoretic immunoblots (EIB). These sera are also referred to as having an indeterminate
HIV
EIB pattern or as
HIV
antibody false positive sera. Seven of nine sera reacted with longer (61-77 amino acids) and none with shorter (17-25 amino acids) p24-derived peptides in enzyme immunoassays (EIAs). This is compatible with a conformational (discontinuous) nature of the epitopes involved in many false positive
HIV
-1 p24 antibody reactions. Four sera reacted with an N-terminal, one with an internal, and two with a C-terminal fragment. Each of the seven sera thus only reacted with one of the long p24 peptides. The specificity and singularity of the reaction was further demonstrated by competition and/or absorption experiments with synthetic peptides. In contrast, 18 of 20 confirmed
HIV
-1+ sera with p24 reactivity in EIB reacted with at least one and often several of the longer peptides, most frequently the C-terminal one. Thus, the distribution of peptide reactivity of true
HIV
-1 antibody-positive sera was different from that of the falsely reactive sera. According to two of several explanations, these antibodies may have arisen because of (1) molecular mimicry by chance or by functional selection, (2) immunization by activation, noninfectious exposure, or infection involving non-
HIV
endogenous or exogenous retroviral antigens. The latter gains some support from our finding of antibody reactions with capsid proteins of the simian viruses, simian sarcoma-associated virus (SSAV), and Mason-Pfizer monkey retrovirus in some of the p24 +/-
p55
reactive sera.
...
PMID:Identification of regions of HIV-1 p24 reactive with sera which give "indeterminate" results in electrophoretic immunoblots with the help of long synthetic peptides. 212 83
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>